Wildcat Capital Management, LLC 13F holdings, Q1 2025
Holdings as of March 31, 2025 · filings on SEC EDGAR · latest filing →
Wildcat Capital Management, LLC disclosed 8 US equity positions worth $187.4m in its Q1 2025 13F filing. The largest position was ULCC at 65.0% of the reported book, followed by RLX and TIC. Against the Q4 2024 filing, it opened 2 new positions, added to 0 and reduced 0 among the top 8 holdings.
What did Wildcat Capital Management, LLC own in Q1 2025? Top 8 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q4 2024 |
|---|---|---|---|---|---|---|---|
| 1 | ULCC FRONTIER GROUP HLDGS INC | Industrials | 65.0% | $121.8m | 28,061,351 | 0% | held |
| 2 | RLX RLX TECHNOLOGY INC | Consumer Defensive | 18.1% | $33.9m | 18,046,195 | 0% | held |
| 3 | TIC ACUREN CORP | 8.9% | $16.7m | 1,500,000 | – | new | |
| 4 | URGN UROGEN PHARMA LTD | Healthcare | 2.9% | $5.5m | 495,606 | 0% | held |
| 5 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 2.3% | $4.3m | 2,920,787 | 0% | held |
| 6 | CNTA CENTESSA PHARMACEUTICALS PLC | 2.2% | $4.1m | 281,859 | – | new | |
| 7 | KRON1USD KRONOS BIO INC | 0.6% | $1.1m | 1,297,959 | 0% | held | |
| 8 | SILEXION THERAPEUTICS CORP | 0.1% | $124.8k | 113,428 | 0% | held |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.